Too many patients and families continue to experience the effects of serious health conditions that have no available treatments or cures.

Covis seeks to collaborate on and acquire promising therapies at various stages of development, and advance them through the clinical and regulatory process to deliver new treatment options to patients.

To further complement and leverage our existing hematology portfolio, we have acquired an investigational drug ciraparantag, an anticoagulant reversal agent, which has not yet been approved by the FDA.

Ciraparantag is being developed for patients treated with novel oral anticoagulants or low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery, urgent procedures or due to life-threatening or uncontrolled bleeding.